Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2012

Arnault Jean Philippe, Mateus Christine, Escudier Bernard, Tomasic Gorana, Wechsler Janine, Hollville Emilie, Soria Jean-Charles, Malka David, Sarasin Alain, Larcher Magalie, André Jocelyne, Kamsu-Kom Nyam, Boussemart Lise, Lacroix Ludovic, Spatz Alain, Eggermont Alexander M, Druillennec Sabine, Vagner Stephan, Eychène Alain, Dumaz Nicolas, Robert Caroline

Abstract excerpt

PURPOSE: The emergence of skin tumors in patients treated with sorafenib or with more recent BRAF inhibitors is an intriguing and potentially serious event. We carried out a clinical, pathologic, and molecular study of skin lesions occurring in patients receiving sorafenib. EXPERIMENTAL DESIGN: Thirty-one skin lesions from patients receiving sorafenib were characterized clinically and pathologically. DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Keratinocytes

Share to Niacinamide

Share to Phenylurea Compounds

Share to raf Kinases

Share to Receptor, Transforming Growth Factor-beta Type I

Share to Receptors, Transforming Growth Factor beta

Share to Sorafenib

Source

Identifiers

PMID: 22096025
DOI: 10.1158/1078-0432.CCR-11-1344

Genes

BRAF
HRAS
TGFBR1
AKT1
EGFR
NRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.PMID 22096025Read ↗

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Semantic proximity Read ↗

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Semantic proximity Read ↗

Somatic oncogenic mutations, benign skin lesions and cancer progression: where to look next?Semantic proximity Read ↗

New insight into BRAF mutations in cancer.Semantic proximity Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.Semantic proximity Read ↗

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Pattern of TGFbeta receptor 1 expression differs between kras-mutated keratoacanthomas and squamous cell carcinomas of the skin.Semantic proximity Read ↗

Keratoacanthoma: a distinct entity?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.